Cea TCB Phase 1B Combination With Apd L1 Study
Research payments
$3,306,652
Through program year 2022, $3,306,652 in research payments was reported against Cea TCB Phase 1B Combination With Apd L1 Study, across 82 payments, paid by Genentech, Inc..
- Paid by
- Genentech, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $481,379 | 7 |
| 2021 | Research | $830,010 | 12 |
| 2020 | Research | $884,415 | 31 |
| 2019 | Research | $1,110,847 | 32 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Neil Segal New York, NY Named on 16 payments
- Christopher Lieu Aurora, CO Named on 12 payments
- Johanna Bendell Nashville, TN Named on 9 payments
- George Fisher Palo Alto, CA Named on 8 payments
- John Strickler Durham, NC Named on 7 payments
- Joseph Eder New Haven, CT Named on 7 payments
- Kanwal Raghav Houston, TX Named on 4 payments
- Jonathan Goldman Santa Monica, CA Named on 4 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.